Selected Publications

Academic Article

Year Title Altmetric
2020 Heparanase and chemotherapy synergize to drive macrophage activation and enhance tumor growthCancer Research.  80:57-68. 2020
2019 Fibronectin on the surface of extracellular vesicles mediates fibroblast invasionAmerican Journal of Respiratory Cell and Molecular Biology.  60:279-288. 2019
2019 Heparanase promotes myeloma stemness and in vivo tumorigenesisCollagen and related research2019
2019 Proteases and glycosidases on the surface of exosomes: Newly discovered mechanisms for extracellular remodelingCollagen and related research.  75-76:160-169. 2019
2018 Phase I study of the heparanase inhibitor roneparstat: An innovative approach for multiple myeloma therapyHaematologica.  103:e469-e472. 2018
2018 Proteoglycan chemical diversity drives multifunctional cell regulation and therapeuticsChemical Reviews.  118:9152-9232. 2018
2018 Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behaviorCollagen and related research.  65:104-118. 2018
2018 Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer ProgressionTrends in Biochemical Sciences.  43:18-31. 2018
2017 Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myelomaBlood Advances.  1:2375-2385. 2017
2017 NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myelomaLeukemia.  31:1648-1650. 2017
2017 Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapyEuropean Journal of Biochemistry.  284:42-55. 2017
2016 Heparanase: From basic research to therapeutic applications in cancer and inflammationDrug Resistance Updates.  29:54-75. 2016
2016 Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotypeCollagen and related research.  55:22-34. 2016
2016 Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: Prevention by synstatinIGF1R inhibits tumor growthCancer Research.  76:4981-4993. 2016
2016 Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.Oncogenesis.  5:e202. 2016
2016 Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell interactionsJournal of Biological Chemistry.  291:1652-1663. 2016
2016 Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical featuresCancer Causes and Control.  27:81-91. 2016
2016 Recent insights into cell surface heparan sulphate proteoglycans and cancer [version 1; referees: 3 approved]F1000Research.  5. 2016
2016 Targeting heparanase overcomes chemoresistance and diminishes relapse in myelomaOncotarget.  7:1598-1607. 2016
2015 Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: A novel mechanism of tumor-host cross-talkJournal of Biological Chemistry.  290:941-949. 2015
2015 Heparanase is a host enzyme required for herpes simplex virus-1 release from cellsNature Communications.  6. 2015
2015 Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.BBA - Biochimica et Biophysica Acta.  1855:276-300. 2015
2014 Chemotherapy stimulates syndecan-1 shedding: A potentially negative effect of treatment that may promote tumor relapseCollagen and related research.  35:215-222. 2014
2014 Heparan sulfate in the nucleus and its control of cellular functionsCollagen and related research.  35:56-59. 2014
2013 Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone diseaseBONE.  57:10-17. 2013
2013 Heparanase: Multiple functions in inflammation, diabetes and atherosclerosisCollagen and related research.  32:220-222. 2013
2013 Involvement of heparanase in atherosclerosis and other vessel wall pathologiesCollagen and related research.  32:241-251. 2013
2013 The heparanase/syndecan-1 axis in cancer: Mechanisms and therapiesEuropean Journal of Biochemistry.  280:2294-2306. 2013
2013 Heparanase regulates secretion, composition, and function of tumor cell-derived exosomesJournal of Biological Chemistry.  288:10093-10099. 2013
2012 Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myelomaJournal of Biological Chemistry.  287:41288-41296. 2012
2012 Targeting heparanase for cancer therapy at the tumor-matrix interfaceCollagen and related research.  31:283-284. 2012
2012 Heparan sulfate chains of syndecan-1 regulate ectodomain sheddingJournal of Biological Chemistry.  287:9952-9961. 2012
2011 Heparanase-mediated loss of nuclear syndecan-1 enhances Histone Acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotypeJournal of Biological Chemistry.  286:30377-30383. 2011
2011 Proteoglycans in cancer biology, tumour microenvironment and angiogenesisJournal of Cellular and Molecular Medicine.  15:1013-1031. 2011
2011 SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axisClinical Cancer Research.  17:1382-1393. 2011
2011 Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activityJournal of Biological Chemistry.  286:6490-6499. 2011
2010 Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKLCancer Research.  70:8329-8338. 2010
2010 Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesisJournal of Bone and Mineral Research.  25:1295-1304. 2010
2010 Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesisBlood.  115:2449-2457. 2010
2010 Proteoglycans in health and disease: New concepts for heparanase function in tumor progression and metastasisEuropean Journal of Biochemistry.  277:3890-3903. 2010
2009 Myeloma bone diseaseJournal of Bone and Mineral Research.  24:1783-1788. 2009
2009 Heparanase: busy at the cell surfaceTrends in Biochemical Sciences.  34:511-519. 2009
2009 Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivoJournal of Biological Chemistry.  284:26085-26095. 2009
2009 Heparanase regulates levels of syndecan-1 in the nucleusPLoS ONE.  4. 2009
2008 Non-anticoagulant heparins and inhibition of cancerHaemostasis.  36:195-203. 2008
2008 Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myelomaJournal of Biological Chemistry.  283:32628-32636. 2008
2008 Non-enzymatic glycation of type I collagen diminishes collagen-proteoglycan binding and weakens cell adhesionJournal of Cellular Biochemistry.  104:1684-1698. 2008
2008 Syndecan-1: A dynamic regulator of the myeloma microenvironmentClinical and Experimental Metastasis.  25:149-159. 2008
2007 The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyBlood.  110:2041-2048. 2007
2007 Heparanase enhances syndecan-1 shedding: A novel mechanism for stimulation of tumor growth and metastasisJournal of Biological Chemistry.  282:13326-13333. 2007
2006 Expression of CD138 (syndecan-1) in renal cell carcinoma is reduced with increasing nuclear gradeApplied Immunohistochemistry and Molecular Morphology.  14:173-177. 2006
2005 HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivoJournal of Biological Chemistry.  280:40066-40073. 2005
2005 Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapiesJournal of Cellular Biochemistry.  96:897-905. 2005
2005 Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastasesCancer Research.  65:5778-5784. 2005
2005 Identification of an invasion regulatory domain within the core protein of syndecan-1Journal of Biological Chemistry.  280:3467-3473. 2005
2005 Heparanase promotes the spontaneous metastasis of myeloma cells to boneBlood.  105:1303-1309. 2005
2005 Dynamic remodeling of syndecan-1 structure regulates myeloma tumor growth and metastasis in vivoTrends in Glycoscience and Glycotechnology.  17:263-270. 2005
2004 Heparan sulfate proteoglycans and heparanase - Partners in osteolytic tumor growth and metastasisCollagen and related research.  23:341-352. 2004
2004 Heparanase degrades syndecan-1 and perlecan heparan sulfate: Functional implications for tumor cell invasionJournal of Biological Chemistry.  279:8047-8055. 2004
2003 High Heparanase Activity in Multiple Myeloma Is Associated with Elevated Microvessel DensityCancer Research.  63:8749-8756. 2003
2003 The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycansBlood.  102:2916-2924. 2003
2003 Heparan sulfate regulates targeting of syndecan-1 to a functional domain on the cell surfaceJournal of Biological Chemistry.  278:12888-12893. 2003
2003 Vitronectin's basic domain is a syndecan ligand which functions in trans to regulate vitronectin turnoverCell Adhesion and Communication.  10:85-103. 2003
2003 Expression of syndecan-1 is a sensitive marker for cutaneous plasmacytomaJournal of Cutaneous Pathology.  30:18-22. 2003
2002 Syndecan-1 in B lymphoid malignanciesAnnals of Hematology.  81:125-135. 2002
2002 Syndecan-1 is strongly expressed in the anagen hair follicle outer root sheath and in the dermal papilla but expression diminishes with involution of the hair follicleAmerican Journal of Dermatopathology.  24:484-489. 2002
2002 Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cellsBlood.  100:3002-3007. 2002
2002 Soluble syndecan-1 promotes growth of myeloma tumors in vivoBlood.  100:610-617. 2002
2002 Neoglycans, carbodiimide-modified glycosaminoglycans: A new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosisCancer Research.  62:3722-3728. 2002
2002 Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cellsBlood.  99:1745-1757. 2002
2002 6xHis promotes binding of a recombinant protein to heparan sulfateBioTechniques.  32:254-258. 2002
2002 Measurements of glycosaminoglycan-based cell interactionsMethods in Cell Biology.  2002:297-308. 2002
2002 The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinomaModern Pathology.  15:45-49. 2002
2001 Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regionsModern Pathology.  14:1052-1058. 2001
2001 Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesionBlood.  98:2160-2165. 2001
2001 Acantholysis and spongiosis are associated with loss of syndecan-1 expressionJournal of Cutaneous Pathology.  28:135-139. 2001
2001 Heparan sulfate proteoglycans in invasion and metastasisSeminars in Cell and Developmental Biology.  12:89-98. 2001
2001 Regulatory roles of syndecans in cell adhesion and invasion.Methods in Molecular Biology.  171:495-503. 2001
2000 High levels of soluble syndecan-1 in myeloma-derived bone marrow: Modulation of hepatocyte growth factor activityBlood.  96:3139-3146. 2000
2000 Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteinsBlood.  96:2528-2536. 2000
2000 The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to β1 integrin-dependent cell spreadingJournal of Cell Biology.  149:1143-1155. 2000
2000 Matrix metalloproteinases in multiple myelomaLeukemia & Lymphoma.  37:273-281. 2000
2000 Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinomaAmerican Journal of Dermatopathology.  22:119-122. 2000
1999 Syndecan-1 expression is diminished in acantholytic cutaneous squamous cell carcinomaJournal of Cutaneous Pathology.  26:386-390. 1999
1999 Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9British Journal of Haematology.  104:365-373. 1999
1999 Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: A multifunctional regulator of cell behavior within the tumor microenvironmentLeukemia & Lymphoma.  34:35-43. 1999
1999 Syndecan-1 expression is induced in the stroma of infiltrating breast carcinomaAmerican Journal of Clinical Pathology.  112:377-383. 1999
1998 Multiple heparan sulfate chains are required for optimal syndecan-1 functionJournal of Biological Chemistry.  273:29965-29971. 1998
1998 Heparan sulfate proteoglycans as adhesive and anti-invasive molecules: Syndecans and glypican have distinct functionsJournal of Biological Chemistry.  273:22825-22832. 1998
1998 Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiationBlood.  91:2679-2688. 1998
1997 Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myelomaBritish Journal of Haematology.  99:368-371. 1997
1996 Heparan sulfate proteoglycans mediate aggregation of human B lymphoid cellsFederation proceedings.  10. 1996
1996 Photoaffmity analogs for the study of glycosaminoglycan biosynthetic enzymes in human myeloma cell linesFederation proceedings.  10. 1996
1995 Heparan sulfate-mediated cell aggregation: Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cellsJournal of Biological Chemistry.  270:5077-5083. 1995
1995 Syndecans as Anti-invasive Molecules on the Surface of Tumor CellsTrends in Glycoscience and Glycotechnology.  7:513-524. 1995
1994 Expression of syndecan-1 inhibits cell invasion into type I collagenJournal of Biological Chemistry.  269:20013-20019. 1994
1994 Interactions of syndecan-1 and heparin with human collagensGlycobiology.  4:327-332. 1994
1994 Fine structure of heparan sulfate regulates syndecan-1 function and cell behaviorJournal of Biological Chemistry.  269:13100-13106. 1994
1994 Interleukin-6 regulates expression of the syndecan-1 proteoglycan on b lymphoid cellsCellular Immunology.  153:456-467. 1994
1993 Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagenBlood.  81:767-774. 1993
1992 Adhesion of B lymphoid (MPC-11) cells to type I collagen is mediated by the integral membrane proteoglycan, syndecanJournal of Immunology.  148:3902-3911. 1992
1992 Functional and molecular characterization of single, (4‐hydroxy‐3‐nitrophenyl)acetyl (NP)‐specific, IgG1+ B cells from antibody‐secreting and memory B cell pathways in the C57BL/6 immune response to NPEuropean Journal of Immunology.  22:3001-3011. 1992
1992 Syndecan-1, a cell-surface proteoglycan, changes in size and abundance when keratinocytes stratifyJournal of Investigative Dermatology.  99:390-396. 1992
1991 Expression of syndecan, a putative low affinity fibroblast growth factor receptor, in the early mouse embryoDevelopment.  113:339-351. 1991
1991 Epithelial-mesenchymal interactions in uterus and vagina alter the expression of the cell surface proteoglycan, syndecanDevelopmental Biology.  148:63-74. 1991
1990 Syndecan, a developmentally regulated cell surface proteoglycan that binds extracellular matrix and growth factors.Philosophical Transactions B: Biological Sciences.  327:171-186. 1990
1989 B lymphocytes express and lose syndecan at specific stages of differentiation.Cell regulation.  1:27-35. 1989
1988 Molecular polymorphism of a cell surface proteoglycan: Distinct structures on simple and stratified epitheliaProceedings of the National Academy of Sciences.  85:9562-9566. 1988
1986 Fibroblasts promote the formation of a continuous basal lamina during myogenesis in vitroJournal of Cell Biology.  102:740-747. 1986
1985 The Extracellular Matrix of Skeletal MuscleCollagen and related research.  5:449-468. 1985
1984 Changes in the synthesis of minor cartilage collagens after growth of chick chondrocytes in 5-bromo-2′-deoxyuridine or to senescenceExperimental Cell Research.  151:171-182. 1984
1984 Monoclonal antibodies against chicken type IV and V collagens: Electron microscopic mapping of the epitopes after rotary shadowingJournal of Cell Biology.  98:1637-1644. 1984
1983 The use of monoclonal antibodies to fragments of chicken type IV collagen in structural and localization studiesJournal of Biological Chemistry.  258:5794-5797. 1983
1983 Monoclonal antibodies against chicken type V collagen: Production, specificity, and use for immunocytochemical localization in embryonic cornea and other organsJournal of Cell Biology.  96:124-132. 1983
1982 Domain and basement membrane specificity of a monoclonal antibody against chicken type IV collagenJournal of Cell Biology.  95:641-647. 1982
1982 Domain and basement membrane specificity of a monoclonal antibody against chicken type IV collagen.Journal of Cell Biology.  95:641-647. 1982


Year Title Altmetric
2010 Proteoglycans and cancer.  191-215. 2010

Principal Investigator On

  • Heparanase In Tumor Progression, Metastasis and Chemoresistance  awarded by National Cancer Institute/NIH/DHHS 2017 - 2022
  • Heparanase Regulation of Tumor Progression Via Exosomes and Autophagosomes  awarded by United States - Israel Binational Science Foundation 2016 - 2020
  • Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy  awarded by National Cancer Institute/NIH/DHHS 2014 - 2020
  • Optimizing Small Molecule Inhibitors of Heparanase for Myeloma Therapy  awarded by Leukemia and Lymphoma Society 2016 - 2019
  • Heparan Sulfate and Cancer Growth Control  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2006 - 2018
  • Private Grant  awarded by SIGMA-TAU RESEARCH, INC. 2012 - 2016
  • Private Grant  awarded by SIGMA-TAU RESEARCH, INC. 2014 - 2015
  • Novel Heparanase Inhibitors for Cancer Therapy  awarded by National Cancer Institute/NIH/DHHS 2010 - 2015
  • Novel Role for Shed Syndecan 1 in Promoting an Aggressive Tumor Phenotype  awarded by National Cancer Institute/NIH/DHHS 2014
  • Nanosight NS300 for Nanoparticle Tracking  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2013 - 2014
  • Novel Heparanase Inhibitors for Myeloma Treatment: Basic Aspects and Clinical Significance  awarded by United States - Israel Binational Science Foundation 2010 - 2014
  • Heparanase Regulation of Tumor Host Interactions in Myeloma and Breast Cancer  awarded by National Cancer Institute/NIH/DHHS 2008 - 2014
  • Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy  awarded by National Cancer Institute/NIH/DHHS 2009 - 2014
  • Synstatin Therapy for Multiple Myeloma  awarded by University of Wisconsin-Madison 2010 - 2013
  • Private Grant  awarded by SIGMA-TAU RESEARCH, INC. 2007 - 2012
  • Heparanase Inhibitor as Anti-Metastatic Therapy for Myeloma.  awarded by Multiple Myeloma Research Foundation 2009 - 2011
  • Investigator On

  • A Novel Exosomal Inflammatory Pathway  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2017 - 2023
  • Molecular Characterization of Myeloma and Related Asymptomatic Precursor States  awarded by National Cancer Institute/NIH/DHHS 2014 - 2020
  • The Thrombospondin1-TGF-Beta Axis in Multiple Myeloma  awarded by National Cancer Institute/NIH/DHHS 2014 - 2019
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Comprehensive Cancer Center Core Support Grant - Cancer Cell Biology Program  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • The Role of Exosome Heparanase and miRNAs as Biomarkers for Myeloma  awarded by National Cancer Institute/NIH/DHHS 2014 - 2018
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Comprehensive Cancer Center Core Support Grant - Cancer Cell Biology Program  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Lumina III System for UAB Optical Imaging  awarded by NIH - OFFICE OF THE DIRECTOR 2016 - 2017
  • HL-A New Pathway for Neutrophil-Induced Airway Inflammation  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016
  • Active - Major Program Leader - Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Gene-Engineered and Targeted Stem Cell Therapy for Myeloma  awarded by National Cancer Institute/NIH/DHHS 2009 - 2016
  • Role of Fumarate Hydratase in Renal Hypoxia and Tumorigenesis  awarded by National Cancer Institute/NIH/DHHS 2012 - 2015
  • Education And Training

  • Doctor of Philosophy in Cell / Cellular Biology and Anatomical Sciences, University of Alabama at Birmingham 1986
  • Full Name

  • Ralph Sanderson